Evidence map›Paper›PMID 33716628›Full record

ReviewBreast care (Basel, Switzerland)2021

The Clinical and Molecular Characteristics of Sex-Determining Region Y-Box 2 and its Prognostic Value in Breast Cancer: A Systematic Meta-Analysis.

Gang Zhao, Xiaozhen Wang, Limei Qu, Zhu Zhu, Jinghui Hong, Haiqin Hou, Zuonong Li, Jun Wang, Zheng Lv

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Breast care (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Gang ZhaoDepartment of Breast Surgery, the First Affiliated Hospital of Jilin University, Changchun, China.
Xiaozhen WangDepartment of Breast Surgery, the First Affiliated Hospital of Jilin University, Changchun, China.
Limei QuDepartment of Pathology, the First Affiliated Hospital of Jilin University, Changchun, China.
Zhu ZhuDepartment of Breast Surgery, the First Affiliated Hospital of Jilin University, Changchun, China.
Jinghui HongDepartment of Breast Surgery, the First Affiliated Hospital of Jilin University, Changchun, China.
Haiqin HouDepartment of Breast Surgery, the First Affiliated Hospital of Jilin University, Changchun, China.
Zuonong LiDepartment of Breast Surgery, the First Affiliated Hospital of Jilin University, Changchun, China.
Jun WangDepartment of Breast Surgery, the First Affiliated Hospital of Jilin University, Changchun, China.
Zheng LvCancer Center, the First Affiliated Hospital of Jilin University, Changchun, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTranscription factor SOX2 (sex-determining region Y-box 2) has a crucial role in the maintenance of the stem cell state. However, current evidence regarding the role of SOX2 in breast cancer is conflicting. We conducted this meta-analysis to clarify the association of SOX2 expression with clinical and molecular features and its prognostic effect on breast cancer.

methodsAll relevant articles were searched using electronic databases. The pooled odds ratios (ORs) or hazard ratios (HRs: multivariate Cox survival analysis) with their 95% confidence intervals (CIs) were calculated.

resultsA final total of 18 studies containing 3,080 patients with breast cancer were included. SOX2 protein expression was not related to age, menopausal status, lymph node metastasis, lymphovascular invasion, molecular estrogen receptor status, progesterone receptor status, triple-negative status, and the overall survival in breast cancer, but was closely associated with advanced tumor grade (grade 3 vs. grade 1-2: OR = 2.74, 95% CI = 1.85-4.06,

conclusionsSOX2 expression is correlated with breast cancer progression, HER2 status, and EGFR status, and may be an independent prognostic marker for predicting poor DFS.

Indexed as

Breast cancerEGFRHER2PrognosisSOX2

Identifiers

PMID33716628
PMCPMC7923910

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.